Schizophrenia studies

A study comparing the effectiveness of Assertive Community Treatment enhanced with evidence based interventions with standard Assertive Community Treatment

This study isn't currently recruiting.

Countries

Netherlands

Sponsor

Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

Adherence therapy for people with schizophrenia in Suanprung Psychiatric Hospital, Thailand

This study isn't currently recruiting.

Countries

United Kingdom, Thailand

Sponsor

Praboromarajanok Institute of Workforce Development (Thailand)

Adherence therapy for people with schizophrenia in Suanprung Psychiatric Hospital, Thailand: a controlled study

This study isn't currently recruiting.

Countries

United Kingdom, Thailand

Sponsor

The Royal Thai Government

An Open Label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

Countries

Bulgaria

Sponsor

Karuna Therapeutics, Inc.

An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Croatia, Latvia

Sponsor

Sunovion Pharmaceuticals Inc.

Cognitive remediation for young people with schizophrenia

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

King's College London (UK) (University)

Evaluation of a Peer-Led Self-Management Programme (PLSMP) for people with schizophrenia

This study isn't currently recruiting.

Countries

Singapore

Sponsor

National University of Singapore (Singapore)

EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

Countries

Spain

Sponsor

Clínica Universidad de Navarra/Universidad de Navarra

Increasing Access to Work for Longer Term Community Mental Health Team (CMHT) clients: the impact of a work-placement training intervention

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

NHS R&D Regional Programme Register - Department of Health (UK)

Interventional, open-label, flexible-dose, long-term safety extension study of Lu AF11167 in patients with schizophrenia

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Czechia, Germany, + 2 others

Sponsor

H. Lundbeck A/S

Long-Term Open-Label Safety Study of Pomaglumetad Methionil in Patients with Schizophrenia

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Belgium, Austria, Germany, + 3 others

Sponsor

Eli Lilly and Company

Modernising teams service delivery: implementing the NICE schizophrenia guideline

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

Department of Health